Clinical trial
Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity
Active, not recruiting · Phase 4 · 1 countries · Registry ID NCT07590219
What this study is about
This randomized controlled trial evaluates the efficacy, safety, metabolic, and cardiovascular effects of liraglutide in children aged 6 to 12 years with severe obesity. Participants are randomized to receive liraglutide plus lifestyle intervention or lifestyle intervention alone for 6 months. In addition to primary outcomes related to weight loss and metabolic improvement, a predefined subgroup analysis evaluates cardiovascular function in participants receiving liraglutide using advanced echocardiographic techniques, including speckle-tracking-derived myocardial deformation parameters.
Basic eligibility
Full registry criteria
Treatments and study arms
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
Liraglutide administered as a once-daily subcutaneous injection, starting at 0.6 mg and titrated weekly up to 3.0 mg or maximum tolerated dose, for 6 months, combined with lifestyle intervention.
Primary outcomes
Body mass index (BMI) will be calculated as body weight in kilograms divided by height in meters squared (kg/m²). BMI will be assessed at baseline and after 6 months using standardized anthropometric measurements.
Study locations
1 locations were listed when this page was built. The first 40 are shown.